Checkpoint Inhibitor Checks in as Treatment for Advanced Gastric Cancers
Despite mixed results in clinical trials, Keytruda is producing promising survival results in some gastric cancer patients and has promise in combination... Read More
Oncologie Pairs PS Inhibitor Bavituximab with Merck’s Keytruda for Gastric Cancer
A new clinical trial pairs Oncologie’s bavituximab with Merck’s Keytruda in advanced stomach or gastroesophageal cancer.
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Leap Therapeutics announced that a combination of its experimental drug DKN-01 and Merck’s Keytruda had a 50% overall response rate in patients... Read More
New Combination Shows Early Promise in Gastric Cancer
A combo of the immuno-oncology drug Keytruda with the VEGFR-2 inhibitor Cyramza was well tolerated by gastric cancer patients in a phase... Read More
Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer
What are the takeaways from recent mixed trial results for Keytruda in gastric cancer? Dr. Mark Zalupski of University of Michigan weighs... Read More